Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
Joanna Zurko(University of Wisconsin–Madison), Reem Karmali(Northwestern University), Jane N. Winter(Northwestern University), Jonathon B. Cohen(Emory University), McKenzie Sorrell(Medical University of South Carolina), Leo I. Gordon(Northwestern University), Geoffrey Shouse(City Of Hope National Medical Center), Kevin A. David(Rutgers, The State University of New Jersey), Stefan K. Barta(University of Pennsylvania), Robert Ferdman(Roswell Park Comprehensive Cancer Center), Vaishalee P. Kenkre(University of Wisconsin–Madison), Deborah M. Stephens(University of North Carolina at Chapel Hill), Audrey M. Sigmund(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Brian Hess(Washington University in St. Louis), Elyse I. Harris(University of Wisconsin–Madison), Barbara Pro(Northwestern University), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Lindsey Fitzgerald(Huntsman Cancer Institute), Rahul S. Bhansali(Hospital of the University of Pennsylvania), Imran Nizamuddin(Northwestern University), Tamara K. Moyo(Carolinas Medical Center), Ishan Roy(Northwestern University), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Adam S. Kittai(The Ohio State University Wexner Medical Center), Nathan Denlinger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jieqi Liu(Rutgers, The State University of New Jersey), Jason T. Romancik(Emory University), Shuo Ma(Nantong University), Carlos Galvez(Northwestern University), Narendranath Epperla(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nirav N. Shah(Medical College of Wisconsin), Sayan Mullick Chowdhury(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Rebecca Masel(Brown University), Thomas Ollila(Brown University)
Cited by 50
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
|American Journal of Hematology|2019|503
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457